We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Full Approval for Trodelvy for Triple-Negative Breast Cancer
FDA Gives Full Approval for Trodelvy for Triple-Negative Breast Cancer
The FDA has granted full approval for Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) for treating women with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior lines of therapy.